WO2022229982A1 - Oral formulations of edaravone and method of manufacturing thereof - Google Patents
Oral formulations of edaravone and method of manufacturing thereof Download PDFInfo
- Publication number
- WO2022229982A1 WO2022229982A1 PCT/IN2022/050399 IN2022050399W WO2022229982A1 WO 2022229982 A1 WO2022229982 A1 WO 2022229982A1 IN 2022050399 W IN2022050399 W IN 2022050399W WO 2022229982 A1 WO2022229982 A1 WO 2022229982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- edaravone
- pharmaceutical composition
- agents
- present
- sublingual
- Prior art date
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title claims abstract description 118
- 229950009041 edaravone Drugs 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 title claims description 62
- 238000009472 formulation Methods 0.000 title description 22
- 238000004519 manufacturing process Methods 0.000 title description 6
- 239000008187 granular material Substances 0.000 claims description 41
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 25
- -1 polyoxyethylene lauryl ether Polymers 0.000 claims description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 17
- 229960000913 crospovidone Drugs 0.000 claims description 16
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 16
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 16
- 238000007906 compression Methods 0.000 claims description 15
- 230000006835 compression Effects 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000314 lubricant Substances 0.000 claims description 13
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 12
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 12
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 12
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 12
- 238000005461 lubrication Methods 0.000 claims description 12
- 229920001993 poloxamer 188 Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 230000035699 permeability Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 239000007968 orange flavor Substances 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 6
- 235000013539 calcium stearate Nutrition 0.000 claims description 6
- 239000008116 calcium stearate Substances 0.000 claims description 6
- 229940078456 calcium stearate Drugs 0.000 claims description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940044519 poloxamer 188 Drugs 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 5
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 5
- 239000008109 sodium starch glycolate Substances 0.000 claims description 5
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 5
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical group 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- LPHFLPKXBKBHRW-UHFFFAOYSA-L magnesium;hydrogen sulfite Chemical compound [Mg+2].OS([O-])=O.OS([O-])=O LPHFLPKXBKBHRW-UHFFFAOYSA-L 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 230000001050 lubricating effect Effects 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000008371 vanilla flavor Substances 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 18
- 239000006186 oral dosage form Substances 0.000 abstract description 5
- 239000003826 tablet Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- 239000002775 capsule Substances 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000006190 sub-lingual tablet Substances 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 229940098466 sublingual tablet Drugs 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 238000005550 wet granulation Methods 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 229940068984 polyvinyl alcohol Drugs 0.000 description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000010579 first pass effect Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 239000006201 parenteral dosage form Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- KGSSUTVUTPLSQW-UHFFFAOYSA-N Robustone Chemical compound C1=C2OCOC2=CC(C2=COC=3C=C4OC(C=CC4=C(O)C=3C2=O)(C)C)=C1 KGSSUTVUTPLSQW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940040064 ubiquinol Drugs 0.000 description 2
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical class O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100033757 Acyl-coenzyme A thioesterase 11 Human genes 0.000 description 1
- 101710169763 Acyl-coenzyme A thioesterase 11 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 150000002170 ethers Chemical group 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009517 secondary packaging Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical group 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
Definitions
- the present invention relates to oral formulation of Edaravone as a tablet. Further, the present invention discloses preferably sublingual tablet composition of Edaravone and pharmaceutically acceptable salt thereof using one or more excipients. Furthermore, the invention relates to providing an economical and technically advanced dosage form over existing parenteral dosage form.
- Edaravone (CAS: 89-25-8) is a member of substituted 2-pyrazolin-5-one chemical moiety. Edaravone is chemically known as [3-methyl-1-phenyl-2-pyrazolin-5-one] and is represented structurally as below:
- Edaravone is marketed presently under the brand name “RADICAVA ® ” in United States. This intravenous infusion is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
- the recommended dosage of Edaravone is 60 mg administered as an intravenous infusion over 60 minutes.
- Mitsubishi Tanabe Pharm Corp. (Osaka, Japan) launched Edaravone under the brand name “RADICUT ® ” in Japan as world's first neurovascular protection drug.
- the recommended dose of Edaravone is 60 mg, which should be administered in the form of two consecutive infusion bags containing 60 mg of Edaravone, i.e. 30 mg per each infusion bag over a period of 60 minutes.
- Each 100 ml infusion bag of RADICAVA ® contains Edaravone, L-cysteine hydrochloride hydrate and sodium bisulfate.
- the pH of the formulation is adjusted with phosphoric acid and sodium hydroxide and the isotonicity is maintained by adding sodium chloride.
- the dosing regimen of Edaravone consist of 2 cycles. Cycle 1 includes an initial treatment cycle with daily dosing for 14 days; followed by a 14-day drug-free period. Subsequent treatment cycles (cycles 2 to 6) are provided with daily dosing for 10 days out of 14-day periods; followed by 14-day drug-free periods.
- Edaravone is prone to oxidation from environmental oxygen. Therefore, Edaravone is supplied in single-dose polypropylene bags, each overwrapped with polyvinyl alcohol (PVA). Further, secondary packaging contains an oxygen absorber with oxygen indicator, which should be pink to reflect appropriate oxygen levels. The oxygen indicator will turn blue or purple if the oxygen has exceeded acceptable levels.
- PVA polyvinyl alcohol
- US6933310 discloses a method for treating motor neuron diseases, amyotrophic lateral sclerosis (ALS), consisting essentially of administering an effective amount of Edaravone or a physiologically acceptable salt thereof to a patient.
- ALS amyotrophic lateral sclerosis
- CN1241565 discloses freeze-dried pharmaceutical composition of Edaravone to facilitate storage and transport.
- Edaravone powder is suspended in water for injection and alkaline material followed by addition of other scaffolds agent to prepare lyophilized dosage form.
- the said invention is not considered as friendly for long-term treatment from the patient compliance point of view. Therefore, there is a need for a patient compliant invention.
- W02009/067343 discloses Edaravone emulsion formulation wherein alcohol, chelating agent and reducing agents are absent. Further, the emulsifier is chosen from egg-yolk phospholipid or soyabean phospholipid. However, during long-term storage, poor stability of this liquid dosage form is a hurdle and requires a novel stable dosage form.
- WO201 2/019381 discloses an oral pharmaceutical composition containing inclusion complex of Edaravone and cyclodextrin.
- This patent comprises mixing Edaravone with cyclodextrin into water for 1 to 2 h. More contact time with water forces Edaravone to oxidize.
- This invention does improve solubility of Edaravone, however, fails to reduce inherent oxidation of Edaravone. Therefore, there is requirement of a novel invention that yields better solubility with significant stability of Edaravone in the oral dosage form.
- WO201 7/157350 discloses a lipid-based drug delivery system comprising Edaravone or a pharmaceutically acceptable salt thereof.
- a solid dispersion is prepared for formulation comprises Edaravone and a polymeric carrier.
- WO201 8/040989 discloses sublingual pharmaceutical compositions of Edaravone and (+)-2-Borneol.
- the sublingual preparation is directly absorbed by sublingual mucosa that has large surface area and strong permeation ability.
- Edaravone is classified under BCS class-IV, i.e., it has low solubility as well as low permeability. Therefore, poor permeability of Edaravone leads poor bioavailability of sublingual dosage form if not prepared a robust one.
- this patent application has reported stability data for 90 days and hence, one cannot predict whether the product is stable afterward or not. Therefore, there is requirement of a novel sublingual invention of Edaravone.
- the present invention discloses the administration of Edaravone in an oral tablet form that does not use sophisticated techniques and is economically affordable compared to parenteral dosage form. Further, the formulated tablet dosage form prepared as per the present invention provides greater stability when compared with marketed Edaravone liquid formulation. Moreover, the oral route is the preferred one for administration in patients with chronic neurodegenerative diseases. In addition, medical practitioners also prefer oral dosage form over injectable dosage forms due to advantages like ease of administration, increased patient compliance, reduced the need for the hospital stay.
- the present invention incorporates Edaravone-HPMC complex that reduce oxidation the drug.
- This complex also increases solubility of Edaravone by providing better dissolution profile and thereby reducing usage of hazardous organic solvents during preparation of tablet.
- the present invention resulted in achieving higher stability of Edaravone as comparing to marketed parenteral dosage form.
- solubility and stability of this patient compliant Edaravone formulation is proven higher when compared to prior art inventions.
- the principal object of the present invention is to provide novel sublingual pharmaceutical formulations of Edaravone and pharmaceutically acceptable salt thereof in the form of tablet which is to be placed under the tongue.
- the sublingual tablet provides better patient compliance; however, none of prior-arts teaches about sublingual formulations for Edaravone.
- Another prime objective of the present invention is to provide dose reduction of Edaravone with the sublingual route by avoiding or reducing drug degradation in the gastric pH and Gl tract metabolism.
- Another prime objective of the present invention is to provide dose reduction of Edaravone with the sublingual route through bypassing first pass metabolism, and thereby reducing excessive metabolism of Edaravone.
- Another aspect is to avoid food effect on the Gl tract absorption of Edaravone thereby reducing plasma concentration variation.
- Another object of the present invention is to achieve a rapid onset of action through sublingual administration because of the high permeability and the rich blood supply to the sub lingual mucosa i.e., under the tongue.
- Another aspect is reduction in the total dose administered through sub lingual route compare to conventional oral route by avoiding the loss of drug dose due to pre-systemic metabolism.
- Yet another object of the present invention is to provide synergistic formulations of Edaravone or pharmaceutically acceptable salt thereof along with one or more pharmaceutically acceptable excipients which are essential for synergistic effect.
- Another object of the present invention is to provide technically advanced patient- compliant dosage forms over existing dosage form and prior-arts.
- the other object of the present invention is to provide reduced dose Edaravone formulations and thereby reducing the cost of final formulations by providing an economic significant dosage form over existing dosage form and prior-arts.
- Yet another objective of the present invention is to provide sublingual oral formulations of Edaravone and one or more pharmaceutically acceptable excipients, excluding (+)-2-borneol with good physical stability over the prior art.
- a pharmaceutical composition comprising Edaravone and one or more pharmaceutically acceptable excipients wherein the composition is in the form of a capsule or a tablet.
- a pharmaceutical composition as per the present invention may be in the form of tablet, capsule, caplet, pellets, beads, granules or powder.
- the present invention provides novel oral compositions of Edaravone preferably as a sublingual tablet dosage form with pharmaceutically acceptable excipients and method of preparation thereof.
- the present invention establishes a very fast release of the pharmaceutical composition during initial dissolution owing to kind of excipients used in the formulation and thereby producing an immediate burst release which in turn immediate absorption of the drug into the blood stream. This action will help to increase bioavailability of Edaravone and pharmaceutically acceptable salt thereof in very short time.
- above-mentioned pharmaceutical composition is optionally provided with barrier coating.
- a pharmaceutical composition as per the present invention comprises Edaravone or pharmaceutically acceptable salt thereof.
- pharmaceutical composition as per the present invention is substantially free of excipients such as pH modifying agents and isotonicity agents.
- a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, higher dose dependent side-effects and bypassing first pass metabolism of Edaravone on the particular target in human body.
- Embodiments of the pharmaceutical composition may include Edaravone as an active ingredient with one or more selected from pharmaceutically acceptable excipients like diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti-oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents, flavouring agent and the like.
- pharmaceutically acceptable excipients like diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti-oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents, flavouring agent and the like.
- a pharmaceutical composition as per the present invention comprises Edaravone or pharmaceutically acceptable salt thereof.
- Edaravone is present in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Edaravone, crystalline Edaravone, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
- composition as per the present invention is in the form of a tablet comprising: a) Edaravone with one or more pharmaceutically acceptable excipients; b) granulating the mixture obtained in a granulator; c) drying the granules followed by blending, lubrication and compression.
- composition as per the present invention is in the form of a capsule comprising: a) Edaravone with diluents, binders, disintegrants and other suitable pharmaceutical excipients followed by lubrication; b) filling of above prepared granules to suitable size of capsule.
- composition as per the present invention is in the form of a capsule comprising: a) Edaravone with diluents, binders, disintegrants and other suitable pharmaceutical excipients followed by lubrication and compression; b) filling of above prepared mini-tablets to suitable size of capsule.
- Edaravone chemically known as, 3-methyl-1 -phenyl-2-pyrazolin-5-one, is a small lipophilic molecule with molecular weight 174.203 g/mol with a solubility of 25pg/ml.
- Edaravone is considered a Bio-pharmaceutics Classification System (BCS) Class IV drug substance due to its poor solubility in water and lower lipid permeability.
- the mean terminal elimination half-life of Edaravone is 4.5 to 6 h.
- a pharmaceutical composition of Edaravone comprising of Edaravone as an active ingredient with pharmaceutically acceptable excipients like carriers, diluents, binders, polymers, chelating agents, anti-oxidants, disintegrating agents, gliding agents, lubricants and the like.
- pharmaceutically acceptable excipients like carriers, diluents, binders, polymers, chelating agents, anti-oxidants, disintegrating agents, gliding agents, lubricants and the like.
- drug or “active ingredient” or “active pharmaceutical ingredient (API)” herein refers to Edaravone or a pharmaceutically acceptable salt thereof.
- Edaravone in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Edaravone, crystalline Edaravone, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
- drug solution includes solution obtained by dissolving Edaravone or its pharmaceutically acceptable salt thereof in solvent and (or) mixture of solvents.
- granulation includes, wet-granulation, dry-granulation or direct compression.
- the excipients of tablet are mainly divided into three parts according to their uses in the manufacturing process (A) intra-granular excipients, (B) excipients used in binder solution, and (C) extra- granular ingredients.
- A intra-granular excipients
- B excipients used in binder solution
- C extra- granular ingredients.
- the list of excipients used are listed in tables below however it is not limited to the said pharmaceutically acceptable excipients.
- pharmaceutically acceptable excipients refers to excipients those are routinely used in pharmaceutical compositions.
- the pharmaceutically acceptable excipients may comprise of diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents, Flavouring agents and combinations thereof.
- Each excipient should be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the health of the patient.
- Suitable fillers or diluents may include one or more of sugars such as lactose, sucrose glucose, fructose, dextrose, galactose, starch; cellulose derivatives such as microcrystalline cellulose; carbonates like calcium carbonate; sugar alcohols such as mannitol, sorbitol, erythritol; magnesium carbonate, calcium phosphates kaolin, magnesium oxide, and combination thereof.
- sugars such as lactose, sucrose glucose, fructose, dextrose, galactose, starch
- cellulose derivatives such as microcrystalline cellulose
- carbonates like calcium carbonate sugar alcohols such as mannitol, sorbitol, erythritol
- magnesium carbonate calcium phosphates kaolin, magnesium oxide, and combination thereof.
- Suitable binders or polymers may include one or more of hydroxyl ethyl cellulose (HEC), hydroxyl propyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), carbomers, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinylpyrrolidone, pre-gelatinized starch, sodium alginate, gums, synthetic resins, silicic acid, hydrophilic polymers and the like.
- HEC hydroxyl ethyl cellulose
- HPC hydroxyl propyl cellulose
- HPMC hydroxypropyl methylcellulose
- carbomers dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinylpyrrolidone, pre-gelatinized starch, sodium alginate, gums, synthetic resins, silicic acid, hydrophilic polymers and the like
- hydrophilic polymers examples include cellulose derivatives, in particular hydrophilic derivatives of the cellulose (e.g. HPMC, HPC, carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose), polyvinylpyrrolidone, copolymers of PVP, preferably co-polymers comprising vinylpyrrolidone, vinyl acetate, poly(oxyethylene) alkyl ether, polyethylene glycol, co-block polymers of ethylene oxide, propylene oxide (poloxamer, Pluronic), derivatives of polymethacrylates, polyvinyl alcohol and derivatives thereof, polyethylene glycol and derivatives thereof.
- cellulose derivatives in particular hydrophilic derivatives of the cellulose (e.g. HPMC, HPC, carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose), polyvinylpyrrolidone, copolymers of PVP, preferably co-polymers comprising vinylpyrrolidone, vinyl acetate, poly
- Suitable organic solvents for preparing binding solution may include one or more of water, organic solvents such as ethanol, isopropyl alcohol, acetone and the like.
- Suitable complexing agent or chelating agent may include one or more of cyclodextrins and derivatives thereof; HPMC (Hypromellose) and derivatives thereof; group consisting of ethylenediamine, calcium disodium edetate, disodium edetate and the like.
- Suitable amino acids may include one or more of cysteine, glycine, arginine, glutamine and derivatives thereof.
- Suitable anti-oxidants may include one or more of sulfites such as sodium bisulfite, magnesium bisulfite; ascorbic acid, metabisulfite, tocopherol, BHT (Butylated hydroxy toluene), BHA, ubiquinol, carotenes, uric acid, lipoic acid, glutathione and the like.
- sulfites such as sodium bisulfite, magnesium bisulfite; ascorbic acid, metabisulfite, tocopherol, BHT (Butylated hydroxy toluene), BHA, ubiquinol, carotenes, uric acid, lipoic acid, glutathione and the like.
- Suitable surfactants or co-surfactants may include one or more of anionic, cationic, non-ionic or amphoteric surfactants.
- Non-limiting examples of surfactants include polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, ethoxylated cholesterins, vitamin derivatives, e.g., vitamin E derivatives such as tocopherol polyethylene glycol succinate (TPGS), sodium dodecyl sulfate or sodium lauryl sulfate; a bile acid or salt thereof, for example cholic acid, glycolic acid or a salt; and the like.
- TPGS tocopherol polyethylene glycol succinate
- TPGS sodium dodecyl sulfate or sodium lauryl sulfate
- a bile acid or salt thereof for example cholic acid, glycolic acid or a salt; and the like.
- Suitable permeability enhancers may include one or more of Propylene glycol monocaprylate; Oleoyl polyoxyl-6 glycerides; Caprylocaproyl polyoxyl-8 glycerides; Propylene glycol monolaurate; diethylene glycol monoethyl ether; pyrrolidones such as N-methylpyrrilidone; cyclodextrins and derivatives thereof; Sulfoxides such as Dimethyl sulfoxide, decylmethalsulfoxide and the like.
- Suitable disintegrating agents may include one or more of crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and the like.
- Suitable gliding agents and lubricating agents may include one or more of talc, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; colloidal silicon dioxide, finely divided silicon dioxide, stearic acid, hydrogenated vegetable oil, glyceryl palmitostearate, glyceryl monostearate, glyceryl behenate, polyethylene glycols, powdered cellulose, starch, sodium stearyl fumarate, sodium benzoate, mineral oil, magnesium trisilicate, kaolin; and the like.
- a wet granulation process for preparing stable sublingual compositions of Edaravone comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) preparing drug solution by dissolving Edaravone and anti-oxidants in a organic solvent and/or surfactant, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) preparing tablets or filled into capsules.
- One embodiment of the present invention may include a pharmaceutical composition comprising about 1 .0% w/w to 40.0% w/w of Edaravone, preferably 3.00% w/w to 34.00% w/w with pharmaceutically acceptable excipients.
- Suitable stabilizers or anti-oxidants may include but are not limited to one or more from butylated hydroxytoluene (BHT), Butylated hydroxy anisole (BHA), tocopherols (Vitamin E), scorbic acid (Vitamin C) or its derivatives, propyl gallate, sodium bisulphite, L-cysteine, magnesium bisulfite, sodium metabisulfite, ubiquinol, b-carotenes, uric acid, lipoic acid, thiourea, glutathione, Pluronic F68 (Poloxamer 188) and fumaric acid and the like.
- BHT butylated hydroxytoluene
- BHA Butylated hydroxy anisole
- tocopherols Vitamin E
- scorbic acid Vitamin C or its derivatives
- propyl gallate sodium bisulphite, L-cysteine
- magnesium bisulfite sodium metabisulfite
- ubiquinol
- the present invention comprises about 0.10% w/w to 5.00% w/w of stabilizer or anti-oxidants of the total composition, preferably in the range of 0.10%w/w to 3.00% w/w of stabilizer or anti-oxidants of the total composition.
- Suitable diluents, fillers, or bulking agents may include but are not limited to one or more from lactose, microcrystalline cellulose, reduced sugars such as monosaccharides like galactose, glucose, glyceraldehyde, fructose, ribose, and xylose; sugar alcohol such as mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol and hydrogenated starch hydrolysates; dibasic calcium phosphate, calcium phosphate, powdered cellulose, calcium carbonate, magnesium carbonate, starch, pre gelatinized starch and the like.
- the inventors of the present invention used different diluents like Mannitol (Pearlitol 25C), Mannitol (Pearlitol 100 SD), F-Melt Type M, Prosolv Easytab SP, Prosolv Easytab SP - LM, PROSOLV ODT G2, Pharmaburst 500, Dexrates (Emdex -Non- GMO), lactose, Dextrose, microcrystalline cellulose, ludipress, pharmaburst, Ultaburst, PEARLITOL flash.
- the inventors of the present invention surprisingly observed at the time of development of sub-lingual tablet that the diluent impacts disintegration (DT) time, tablet properties and impurity.
- the inventors of the present invention observed problems of Tablet DT and Tablet surface roughness and moisture uptake on storage.
- Suitable binders may include but are not limited to one or more from hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (povidone), gum arabic and sugars such as sucrose, glucose, dextrose, lactose, polyvinyl alcohol and the like.
- Suitable disintegrants may include but are not limited to one or more from crospovidone, croscarmellose sodium, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and the like.
- the present invention comprises about 1% w/w to 25% w/w of disintegrants of the total composition, preferably in the range of 3%w/w to 20% w/w of disintegrants of the total composition.
- disintegration time of Sodium starch glycolate was not achieved at different levels.
- disintegration time of crospovidone was achieved with different grades and levels but the tablet surface was very rough.
- tablets made with crospovidone absorbed moisture and swelled.
- the inventors of the present invention noted that roughness on the tablet surface was observed due to the moisture absorption by crospovidone.
- Suitable wetting agents or surfactants or solubilizers may include but are not limited to one or more from the group comprising anionic, cationic, nonionic, or zwitterionic surfactants, or combinations thereof.
- wetting agents are sodium lauryl sulphate, cetrimide, polyethylene glycols, polyoxyethylene- polyoxypropylene block copolymers such as poloxamers, pluronic F68, polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate, sorbitan fatty acid esters such as sorbitan monostearate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate, polyethylene glycol fatty acid esters such as polyoxyethylene monostearate, polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene castor oil, sepitrap 80, polysorbate 80 and the like.
- the present invention comprises about
- SLS Lauryl Sulfate
- SEPITRAP 80 is a micro-encapsulated solubilizer in powder form designed to simplify the manufacturing of solid oral form drugs. It is manufactured by adsorption of the solubilizer in liquid form on a porous support. It contains Polysorbate 80 adsorbed on Magnesium Alumino metasilicate. The inventors of the present invention found Sepitrap 80 as beneficial because it helped to provide a better dissolution profile.
- Suitable lubricants may include but are not limited to one or more from fatty acids, fatty acid salts, and fatty acid esters such as magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, colloidal silicon dioxide and mixtures thereof.
- the present invention comprises about 1 -15% w/w of lubricants of the total composition, preferably in the range of 1 -8% w/w of lubricants of the total composition.
- the inventors of the present invention surprisingly found that being water-soluble lubricant, Sodium stearyl fumarate provided better dissolution profile than water insoluble lubricants like Magnesium stearate.
- the inventors of the present invention observed that colloidal silicon dioxide improved wet granulation process. Hence, the combination of these inactive ingredients provided a synergistic effect.
- Suitable permeability enhancers may include but are not limited to one or more from the group comprising alcohols, Polyols, short-chain glycerides, amines, amides, cyclodextrins, fatty acids, pyrrolidines, azones, sulfoxides, surfactants, terpenes and the like.
- Suitable chelating or complexing agents may include but are not limited to one or more from the group comprising cyclodextrin, ethylenediamine tetra acetic acid or derivatives/salts thereof, e.g., disodium edetate, dihydroxyethyl glycine, glucamine, citric acid, tartaric acid, gluconic acid, phosphoric acid and the like.
- Suitable coloring and flavoring agents may include but are not limited to one or more from sucralose, maltose, orange flavor, vanilla flavor and the like. Being zero- calorie artificial flavoring agent, Sucralose and orange flavour were used in the formulation. Hence, the patients with diabetes can also take this medicine and thus, the present invention provided better patient compliance.
- the present invention comprises about less than 3%w/w of flavoring agents of the total composition, preferably less than 1%w/w of flavoring agents of the total composition.
- the inventors of the present invention also optimized the hardness of the tablet and disintegration time of the tablet by the selection of suitable punch tolling.
- the prime aspect of the present invention is that the pharmaceutical composition establishes a fast release pattern owing to the kind of excipients used in the formulation and thereby producing an immediate release that will in turn increase in bioavailability at initial release.
- a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, reduction in dose dependent side-effects and bypassing first pass metabolism of Edaravone on the particular target in human body.
- One aspect of the present invention may include a pharmaceutical composition comprising about 1%w/w to 40%w/w of Edaravone with pharmaceutically acceptable excipients.
- the pharmaceutical composition manufactured is sublingual tablet, which results in to enhanced dissolution profile.
- formulated product manufactured is homogenous dispersions, which results in to enhanced dissolution profile and stability profile.
- composition manufactured by number of stages in manufacturing process including mixing, wet-granulation and compression.
- the formulated product is a stabilized sublingual tablet.
- process for preparation of an oral pharmaceutical composition as per the present invention comprising following steps: 1 . Co-milling of Mannitol, crospovidone and colloidal silicon dioxide through #40 sieve;
- step-6 Lubricating the blend obtained in step-6 with magnesium stearate or calcium stearate or sodium stearyl fumarate.
- step-7 Compressing the lubricated blend obtained in step-7 to form tablets.
- compositions as described herein may be prepared by processes known to the person having ordinary skill in the art of pharmaceutical technology such as direct compression, wet granulation, dry granulation or hot melt granulation.
- Step-1 Preparation of binding solution:
- Binding solution prepared as per step-1 is admixed with premixed excipients lactose and crospovidone to prepare granules in a granulator. The granules are dried and sized.
- Step-3 Lubrication:
- the dried and sized granules prepared as per step-2 are lubricated with magnesium stearate and Crospovidone.
- Step-4a Compression: The lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
- Step-4b Capsule filling: The lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
- the tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
- Step-1 Preparation of binding solution: Edaravone, Hypromellose, L-cysteine, Sodium Bisulfite are mixed to prepare binding solution using purified water with ethanol (Example-3) OR isopropyl alcohol (Example-4).
- Step-2 Preparation of granules:
- Binding solution prepared as per step-1 is admixed with premixed excipients lactose and crospovidone to prepare granules in a granulator.
- the granules are dried and sized.
- the dried and sized granules prepared as per step-2 are lubricated with magnesium stearate and Crospovidone.
- Step-4a Compression:
- the lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
- Step-4b Capsule filling:
- the lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
- the tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
- Step-1 Preparation of binding solution:
- Step-2 Preparation of granules:
- Binding solution prepared as per step-1 is admixed with premixed excipients mannitol, crospovidone and colloidal silicone dioxide to prepare granules in a granulator. The granules are dried and sized.
- the dried and sized granules prepared as per step-2 are lubricated with magnesium stearate or calcium stearate, Sucralose, Sepitrap 80 (Polysorbate 80 and Magnesium Aluminometasilicate) and Crospovidone.
- Step-4a Compression:
- the lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
- Step-4b Capsule filling:
- the lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
- the tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
- EXAMPLE- 6 is optionally coated with pharmaceutically acceptable coating agents.
- Step-1 Preparation of binding solution:
- Binding solution prepared as per step-1 is admixed with premixed excipients Prosolv Easytab SP - LM /Prosolv Easytab SP / F melt , Sodium lauryl Sulfate and Colloidal silicone dioxide to prepare granules in a granulator. The granules are dried and sized.
- Step-4a Compression:
- Step-4b Capsule filling:
- the lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
- Step-1 Preparation of binding solution:
- Binding solution prepared as per step-1 is admixed with premixed excipients Mannitol or Lactose or Dextrose or microcrystalline cellulose or Ludipress or Pharmaburst or Ultraburst or What is Ludiflash or PEARLITOL Flash, L- cysteine, Croscarmellose Sodium or Sodium Starch glycolate or Starch and Colloidal silicone dioxide to prepare granules in a granulator. The granules are dried and sized.
- the dried and sized granules prepared as per step-2 are lubricated with magnesium stearate.
- Step-4a Compression:
- the lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
- Step-4b Capsule filling:
- the lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
- the tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
Abstract
The present invention relates to oral dosage form of Edaravone. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing marketed dosage form. The present invention further relates to sublingual oral dosage-form of Edaravone which is orally bioavailable as well as stable for a longer period.
Description
“ORAL FORMULATIONS OF EDARAVONE AND METHOD OF MANUFACTURING THEREOF”
FIELD OF THE INVENTION: The present invention relates to oral formulation of Edaravone as a tablet. Further, the present invention discloses preferably sublingual tablet composition of Edaravone and pharmaceutically acceptable salt thereof using one or more excipients. Furthermore, the invention relates to providing an economical and technically advanced dosage form over existing parenteral dosage form.
BACKGROUND OF THE INVENTION:
Edaravone (CAS: 89-25-8) is a member of substituted 2-pyrazolin-5-one chemical moiety. Edaravone is chemically known as [3-methyl-1-phenyl-2-pyrazolin-5-one] and is represented structurally as below:
EDARAVONE ®
Edaravone, a very old molecule, is disclosed earlier during 1925 in DE473214. The said German patent discloses a process for the preparation of 1 -phenyl-3- methylpyrazolone by the oxidation of 1 -phenyl-3-methylpyrazolidone in aqueous hydrochloric acid solution and in the presence of oxygen-transferring metal salts, characterized by the use of oxygen or oxygen-containing metal salts gases as oxidizing agents.
Edaravone is marketed presently under the brand name “RADICAVA®” in United States. This intravenous infusion is indicated for the treatment of amyotrophic lateral sclerosis (ALS). The recommended dosage of Edaravone is 60 mg administered as an intravenous infusion over 60 minutes. Prior to US approval, Mitsubishi Tanabe Pharm Corp. (Osaka, Japan) launched Edaravone under the brand name “RADICUT®” in Japan as world's first neurovascular protection drug.
The recommended dose of Edaravone is 60 mg, which should be administered in the form of two consecutive infusion bags containing 60 mg of Edaravone, i.e. 30 mg per each infusion bag over a period of 60 minutes. Each 100 ml infusion bag of RADICAVA® contains Edaravone, L-cysteine hydrochloride hydrate and sodium bisulfate. The pH of the formulation is adjusted with phosphoric acid and sodium hydroxide and the isotonicity is maintained by adding sodium chloride. The dosing regimen of Edaravone consist of 2 cycles. Cycle 1 includes an initial treatment cycle with daily dosing for 14 days; followed by a 14-day drug-free period. Subsequent treatment cycles (cycles 2 to 6) are provided with daily dosing for 10 days out of 14-day periods; followed by 14-day drug-free periods.
Edaravone is prone to oxidation from environmental oxygen. Therefore, Edaravone is supplied in single-dose polypropylene bags, each overwrapped with polyvinyl alcohol (PVA). Further, secondary packaging contains an oxygen absorber with oxygen indicator, which should be pink to reflect appropriate oxygen levels. The oxygen indicator will turn blue or purple if the oxygen has exceeded acceptable levels.
US6933310 discloses a method for treating motor neuron diseases, amyotrophic lateral sclerosis (ALS), consisting essentially of administering an effective amount of Edaravone or a physiologically acceptable salt thereof to a patient.
CN1241565 discloses freeze-dried pharmaceutical composition of Edaravone to facilitate storage and transport. As per this Chinese patent, Edaravone powder is suspended in water for injection and alkaline material followed by addition of other scaffolds agent to prepare lyophilized dosage form. However, the said invention is not considered as friendly for long-term treatment from the patient compliance point of view. Therefore, there is a need for a patient compliant invention.
W02009/067343 discloses Edaravone emulsion formulation wherein alcohol, chelating agent and reducing agents are absent. Further, the emulsifier is chosen from egg-yolk phospholipid or soyabean phospholipid. However, during long-term storage, poor stability of this liquid dosage form is a hurdle and requires a novel stable dosage form.
WO201 2/019381 discloses an oral pharmaceutical composition containing inclusion complex of Edaravone and cyclodextrin. This patent comprises mixing Edaravone with cyclodextrin into water for 1 to 2 h. More contact time with water forces Edaravone to oxidize. This invention does improve solubility of Edaravone, however, fails to reduce inherent oxidation of Edaravone. Therefore, there is requirement of a novel invention that yields better solubility with significant stability of Edaravone in the oral dosage form.
WO201 7/157350 discloses a lipid-based drug delivery system comprising Edaravone or a pharmaceutically acceptable salt thereof. A solid dispersion is prepared for formulation comprises Edaravone and a polymeric carrier. However, preparing solid dispersion of Edaravone needs reduction in particle size of API and reduction in particle size yield larger surface area to Edaravone. Thereby, producing higher chance of oxidation to Edaravone due to larger surface area of particles. Therefore, this invention also fails to minimize oxidative effect on Edaravone.
WO201 8/040989 discloses sublingual pharmaceutical compositions of Edaravone and (+)-2-Borneol. The sublingual preparation is directly absorbed by sublingual mucosa that has large surface area and strong permeation ability. However, Edaravone is classified under BCS class-IV, i.e., it has low solubility as well as low permeability. Therefore, poor permeability of Edaravone leads poor bioavailability of sublingual dosage form if not prepared a robust one. Further, this patent application has reported stability data for 90 days and hence, one cannot predict whether the product is stable afterward or not. Therefore, there is requirement of a novel sublingual invention of Edaravone.
At present, market availability of only injectable Edaravone formulation need an additional Edaravone dosage form. From patient's compliance point of view, parenteral formulation is not suitable for long-term therapy. Therefore, the inventors of the present invention have developed an oral dosage form of Edaravone.
The present invention discloses the administration of Edaravone in an oral tablet form that does not use sophisticated techniques and is economically affordable compared to parenteral dosage form. Further, the formulated tablet dosage form prepared as per the present invention provides greater stability when compared with marketed Edaravone liquid formulation. Moreover, the oral route is the preferred one for administration in patients with chronic neurodegenerative diseases. In addition, medical practitioners also prefer oral dosage form over injectable dosage forms due to advantages like ease of administration, increased patient compliance, reduced the need for the hospital stay.
The present invention incorporates Edaravone-HPMC complex that reduce oxidation the drug. This complex also increases solubility of Edaravone by providing better dissolution profile and thereby reducing usage of hazardous organic solvents during preparation of tablet. Moreover, the present invention resulted in achieving higher stability of Edaravone as comparing to marketed parenteral dosage form. Moreover, as per the present invention, solubility and stability of this patient compliant Edaravone formulation is proven higher when compared to prior art inventions.
Hence, the inventors of the present invention felt that still, there is an unmet need to develop a dosage form of Edaravone, which overcome the drawbacks of prior available formulations and has good physical stability, cost effective, can be produced by simple manufacturing techniques and can maximize the permeability of Edaravone from such dosage form and thereby improve its bioavailability with patient compliance.
OBJECTIVES OF THE INVENTION:
The principal object of the present invention is to provide novel sublingual pharmaceutical formulations of Edaravone and pharmaceutically acceptable salt thereof in the form of tablet which is to be placed under the tongue. The sublingual tablet provides better patient compliance; however, none of prior-arts teaches about sublingual formulations for Edaravone.
Another prime objective of the present invention is to provide dose reduction of Edaravone with the sublingual route by avoiding or reducing drug degradation in the gastric pH and Gl tract metabolism.
Another prime objective of the present invention is to provide dose reduction of Edaravone with the sublingual route through bypassing first pass metabolism, and thereby reducing excessive metabolism of Edaravone.
Further, another aspect is to avoid food effect on the Gl tract absorption of Edaravone thereby reducing plasma concentration variation.
Furthermore, another object of the present invention is to achieve a rapid onset of action through sublingual administration because of the high permeability and the rich blood supply to the sub lingual mucosa i.e., under the tongue.
Moreover, another aspect is reduction in the total dose administered through sub lingual route compare to conventional oral route by avoiding the loss of drug dose due to pre-systemic metabolism.
Yet another object of the present invention is to provide synergistic formulations of Edaravone or pharmaceutically acceptable salt thereof along with one or more pharmaceutically acceptable excipients which are essential for synergistic effect.
Another object of the present invention is to provide technically advanced patient- compliant dosage forms over existing dosage form and prior-arts.
The other object of the present invention is to provide reduced dose Edaravone formulations and thereby reducing the cost of final formulations by providing an economic significant dosage form over existing dosage form and prior-arts.
Yet another objective of the present invention is to provide sublingual oral formulations of Edaravone and one or more pharmaceutically acceptable excipients, excluding (+)-2-borneol with good physical stability over the prior art.
SUMMARY OF THE INVENTION
Notwithstanding of wide research on Edaravone as reported in prior-art publications, there is an unmet need to develop a patient compliant oral sublingual composition for Edaravone with technical advancement which provide fast dissolution for immediate action as well as good stability for at least more than two- year storage. This dosage form also increases patient compliance because patient feels difficulty in taking conventional tablet or dispersible tablets when he or she is outdoor; whereas sublingual tablet does not require even water. Thus, the present invention has solved the problem that is present in the prior-arts as well as in the existing marketed formulations.
In one general aspect, a pharmaceutical composition comprising Edaravone and one or more pharmaceutically acceptable excipients wherein the composition is in the form of a capsule or a tablet.
In another general aspect, a pharmaceutical composition as per the present invention may be in the form of tablet, capsule, caplet, pellets, beads, granules or powder.
Accordingly, the present invention provides novel oral compositions of Edaravone preferably as a sublingual tablet dosage form with pharmaceutically acceptable excipients and method of preparation thereof.
The present invention establishes a very fast release of the pharmaceutical composition during initial dissolution owing to kind of excipients used in the formulation and thereby producing an immediate burst release which in turn immediate absorption of the drug into the blood stream. This action will help to increase bioavailability of Edaravone and pharmaceutically acceptable salt thereof in very short time.
In another general aspect, above-mentioned pharmaceutical composition is optionally provided with barrier coating.
In another general aspect, a pharmaceutical composition as per the present invention comprises Edaravone or pharmaceutically acceptable salt thereof.
In yet another general aspect, pharmaceutical composition as per the present invention is substantially free of excipients such as pH modifying agents and isotonicity agents.
In another embodiment of the present invention, a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, higher dose dependent side-effects and bypassing first pass metabolism of Edaravone on the particular target in human body.
Embodiments of the pharmaceutical composition may include Edaravone as an active ingredient with one or more selected from pharmaceutically acceptable excipients like diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti-oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents, flavouring agent and the like.
In another general embodiment of the present invention, a pharmaceutical composition as per the present invention comprises Edaravone or pharmaceutically acceptable salt thereof. Preferably, Edaravone is present in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Edaravone, crystalline Edaravone, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
In another embodiment, pharmaceutical composition as per the present invention is in the form of a tablet comprising: a) Edaravone with one or more pharmaceutically acceptable excipients; b) granulating the mixture obtained in a granulator; c) drying the granules followed by blending, lubrication and compression.
In yet another general aspect, pharmaceutical composition as per the present invention is in the form of a capsule comprising: a) Edaravone with diluents, binders, disintegrants and other suitable pharmaceutical excipients followed by lubrication; b) filling of above prepared granules to suitable size of capsule.
In yet another general aspect, pharmaceutical composition as per the present invention is in the form of a capsule comprising: a) Edaravone with diluents, binders, disintegrants and other suitable pharmaceutical excipients followed by lubrication and compression; b) filling of above prepared mini-tablets to suitable size of capsule.
In another embodiment of the present invention, the pharmaceutical composition is in the form of sublingual tablets is/are prepared by wet granulation process comprises a step for providing Edaravone, wherein the Edaravone is contained in a sublingual tablet that may be prepared by the steps comprising: (a) dispensing of all raw material, (b) sifting one or more pharmaceutically acceptable excipients, (c) binder solution preparation by using binders and anti-oxidants in solvent and surfactant, (d) granulating by the rapid mixer granulator and/or the top spray granulating, (e) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (g) preparing tablets or filled into capsules.
The details of one or more embodiments of the invention are set forth in the description below. Other features of the invention will be apparent from the description.
DETAILED DESCRIPTION OF THE INVENTION:
The following detailed description of the present subject matter the various embodiments. These embodiments are described in sufficient detail to enable those skilled in the art to practice the present subject matter. Other embodiments may be utilized and structural, logical, and electrical changes may be made without departing from the scope of the present subject matter.
Further, the present invention will now be disclosed by describing certain preferred and optional embodiments, to facilitate various aspects thereof.
References to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope is defined only by the appended claims, along with the full scope of legal equivalents to which such claims are entitled.
Edaravone, chemically known as, 3-methyl-1 -phenyl-2-pyrazolin-5-one, is a small lipophilic molecule with molecular weight 174.203 g/mol with a solubility of 25pg/ml. Edaravone is considered a Bio-pharmaceutics Classification System (BCS) Class IV drug substance due to its poor solubility in water and lower lipid permeability. The mean terminal elimination half-life of Edaravone is 4.5 to 6 h.
In accordance with the present invention, a pharmaceutical composition of Edaravone comprising of Edaravone as an active ingredient with pharmaceutically acceptable excipients like carriers, diluents, binders, polymers, chelating agents, anti-oxidants, disintegrating agents, gliding agents, lubricants and the like.
The term "drug" or “active ingredient” or “active pharmaceutical ingredient (API)” herein refers to Edaravone or a pharmaceutically acceptable salt thereof.
The term "Edaravone" as used herein according to the present invention includes, Edaravone in the form of free base, a pharmaceutically acceptable salt thereof, amorphous Edaravone, crystalline Edaravone, any isomer, derivative, hydrate, solvate or prodrug or a combination thereof.
The term "drug solution" as used herein according to the present invention includes solution obtained by dissolving Edaravone or its pharmaceutically acceptable salt thereof in solvent and (or) mixture of solvents.
The term "granulation" as used herein according to the present invention includes, wet-granulation, dry-granulation or direct compression.
At the time of preparation of the dosage form, the excipients of tablet are mainly divided into three parts according to their uses in the manufacturing process (A) intra-granular excipients, (B) excipients used in binder solution, and (C) extra- granular ingredients. The list of excipients used are listed in tables below however it is not limited to the said pharmaceutically acceptable excipients.
The term "pharmaceutically acceptable excipients" as used herein, refers to excipients those are routinely used in pharmaceutical compositions. The pharmaceutically acceptable excipients may comprise of diluents, disintegrants, binders, lubricants, vehicles / solubility enhancing agents, stabilizers / anti oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents, Flavouring agents and combinations thereof. Each excipient should be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the health of the patient.
Suitable fillers or diluents may include one or more of sugars such as lactose, sucrose glucose, fructose, dextrose, galactose, starch; cellulose derivatives such as microcrystalline cellulose; carbonates like calcium carbonate; sugar alcohols such as mannitol, sorbitol, erythritol; magnesium carbonate, calcium phosphates kaolin, magnesium oxide, and combination thereof.
Suitable binders or polymers may include one or more of hydroxyl ethyl cellulose (HEC), hydroxyl propyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), carbomers, dextrin, ethyl cellulose, methylcellulose, shellac, zein, gelatin, polymethacrylates, polyvinylpyrrolidone, pre-gelatinized starch, sodium alginate, gums, synthetic resins, silicic acid, hydrophilic polymers and the like.
The term "hydrophilic polymer" comprises polymers with polar groups such as hydroxy, amino, carboxy, carbonyl, ethers, esters and sulfonates. Examples of suitable hydrophilic polymers are cellulose derivatives, in particular hydrophilic derivatives of the cellulose (e.g. HPMC, HPC, carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose), polyvinylpyrrolidone, copolymers of PVP, preferably co-polymers comprising vinylpyrrolidone, vinyl acetate, poly(oxyethylene) alkyl ether, polyethylene glycol, co-block polymers of ethylene oxide, propylene oxide (poloxamer, Pluronic), derivatives of polymethacrylates, polyvinyl alcohol and derivatives thereof, polyethylene glycol and derivatives thereof.
Suitable organic solvents for preparing binding solution may include one or more of water, organic solvents such as ethanol, isopropyl alcohol, acetone and the like.
Suitable complexing agent or chelating agent may include one or more of cyclodextrins and derivatives thereof; HPMC (Hypromellose) and derivatives thereof; group consisting of ethylenediamine, calcium disodium edetate, disodium edetate and the like.
Suitable amino acids may include one or more of cysteine, glycine, arginine, glutamine and derivatives thereof.
Suitable anti-oxidants may include one or more of sulfites such as sodium bisulfite, magnesium bisulfite; ascorbic acid, metabisulfite, tocopherol, BHT (Butylated hydroxy toluene), BHA, ubiquinol, carotenes, uric acid, lipoic acid, glutathione and the like.
Suitable surfactants or co-surfactants may include one or more of anionic, cationic, non-ionic or amphoteric surfactants. Non-limiting examples of surfactants include polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, ethoxylated cholesterins, vitamin derivatives, e.g., vitamin E derivatives such as tocopherol polyethylene glycol succinate (TPGS), sodium dodecyl sulfate or sodium lauryl sulfate; a bile acid or salt thereof, for example cholic acid, glycolic acid or a salt; and the like.
Suitable permeability enhancers may include one or more of Propylene glycol monocaprylate; Oleoyl polyoxyl-6 glycerides; Caprylocaproyl polyoxyl-8 glycerides; Propylene glycol monolaurate; diethylene glycol monoethyl ether; pyrrolidones such as N-methylpyrrilidone; cyclodextrins and derivatives thereof; Sulfoxides such as Dimethyl sulfoxide, decylmethalsulfoxide and the like.
Suitable disintegrating agents may include one or more of crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and the like.
Suitable gliding agents and lubricating agents may include one or more of talc, metallic stearates such as magnesium stearate, calcium stearate, zinc stearate; colloidal silicon dioxide, finely divided silicon dioxide, stearic acid, hydrogenated vegetable oil, glyceryl palmitostearate, glyceryl monostearate, glyceryl behenate, polyethylene glycols, powdered cellulose, starch, sodium stearyl fumarate, sodium benzoate, mineral oil, magnesium trisilicate, kaolin; and the like.
In accordance with the present invention, it provides a wet granulation process for preparing stable sublingual compositions of Edaravone comprising the steps of: (a) sifting one or more pharmaceutically acceptable excipients, (b) preparing drug solution by dissolving Edaravone and anti-oxidants in a organic solvent and/or surfactant, (c) granulating the dry mix of step (a) with the drug solution of step (b) to obtain wet mass, (d) drying and sieving the wet mass to obtain granules, (e) blending the granules of step (d) with extra granular excipients if any, followed by lubrication and (f) compressing the lubricated blend of step (e) preparing tablets or filled into capsules.
One embodiment of the present invention may include a pharmaceutical composition comprising about 1 .0% w/w to 40.0% w/w of Edaravone, preferably 3.00% w/w to 34.00% w/w with pharmaceutically acceptable excipients.
Suitable stabilizers or anti-oxidants may include but are not limited to one or more from butylated hydroxytoluene (BHT), Butylated hydroxy anisole (BHA), tocopherols (Vitamin E), scorbic acid (Vitamin C) or its derivatives, propyl gallate, sodium bisulphite, L-cysteine, magnesium bisulfite, sodium metabisulfite, ubiquinol, b-carotenes, uric acid, lipoic acid, thiourea, glutathione, Pluronic F68 (Poloxamer 188) and fumaric acid and the like. The inventors of the present invention surprisingly found that BHT provided better stability than other anti oxidants. The present invention comprises about 0.10% w/w to 5.00% w/w of stabilizer or anti-oxidants of the total composition, preferably in the range of 0.10%w/w to 3.00% w/w of stabilizer or anti-oxidants of the total composition.
Suitable diluents, fillers, or bulking agents may include but are not limited to one or more from lactose, microcrystalline cellulose, reduced sugars such as monosaccharides like galactose, glucose, glyceraldehyde, fructose, ribose, and xylose; sugar alcohol such as mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol and hydrogenated starch hydrolysates; dibasic calcium phosphate, calcium phosphate, powdered cellulose, calcium carbonate, magnesium carbonate, starch, pre gelatinized starch and the like.
The inventors of the present invention used different diluents like Mannitol (Pearlitol 25C), Mannitol (Pearlitol 100 SD), F-Melt Type M, Prosolv Easytab SP, Prosolv Easytab SP - LM, PROSOLV ODT G2, Pharmaburst 500, Dexrates (Emdex -Non-
GMO), lactose, Dextrose, microcrystalline cellulose, ludipress, pharmaburst, Ultaburst, PEARLITOL flash.
The inventors of the present invention surprisingly observed at the time of development of sub-lingual tablet that the diluent impacts disintegration (DT) time, tablet properties and impurity. The inventors of the present invention observed problems of Tablet DT and Tablet surface roughness and moisture uptake on storage.
Suitable binders may include but are not limited to one or more from hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (povidone), gum arabic and sugars such as sucrose, glucose, dextrose, lactose, polyvinyl alcohol and the like.
Suitable disintegrants may include but are not limited to one or more from crospovidone, croscarmellose sodium, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and the like. The present invention comprises about 1% w/w to 25% w/w of disintegrants of the total composition, preferably in the range of 3%w/w to 20% w/w of disintegrants of the total composition.
The inventors of the present invention observed that disintegration time of Sodium starch glycolate was not achieved at different levels. Surprisingly, disintegration time of crospovidone was achieved with different grades and levels but the tablet surface was very rough. In addition, tablets made with crospovidone absorbed moisture and swelled. The inventors of the present invention noted that roughness on the tablet surface was observed due to the moisture absorption by crospovidone.
Surprisingly, when the inventors of the present invention combined Prosolv Easytab SP - LM in optimum concentration in combination with croscarmellose sodium, the rough surface tablet problem was solved and optimum disintegration time was also achieved. Thus, synergistic effect was observed by the inventors of the present invention by combining these two inactive ingredients. In addition, this excipient combination also provided rapid dissolution which is prime requirement of sub-lingual route. Furthermore, this combination of excipients also improved mouthfeel than other excipients which is also the requirement for the sub-lingual route.
Suitable wetting agents or surfactants or solubilizers may include but are not limited to one or more from the group comprising anionic, cationic, nonionic, or zwitterionic surfactants, or combinations thereof. Suitable examples of wetting agents are sodium lauryl sulphate, cetrimide, polyethylene glycols, polyoxyethylene- polyoxypropylene block copolymers such as poloxamers, pluronic F68,
polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate, sorbitan fatty acid esters such as sorbitan monostearate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate, polyethylene glycol fatty acid esters such as polyoxyethylene monostearate, polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene castor oil, sepitrap 80, polysorbate 80 and the like. The present invention comprises about 0.10%w/w to 20%w/w of solubilizers of the total composition, preferably in the range of 0.10%w/w to 15%w/w of solubilizers of the total composition.
The inventors of the present invention surprisingly found that Sodium Lauryl Sulfate [SLS] (brand: Kolliphor SLS Fine, Kolliphor P188) improved dissolution in different dissolution media. Hence, it shows that the final formulation is showing the same dissolution nature in any pH of the dissolution media and hence, is more stable in releasing profile.
SEPITRAP 80 is a micro-encapsulated solubilizer in powder form designed to simplify the manufacturing of solid oral form drugs. It is manufactured by adsorption of the solubilizer in liquid form on a porous support. It contains Polysorbate 80 adsorbed on Magnesium Alumino metasilicate. The inventors of the present invention found Sepitrap 80 as beneficial because it helped to provide a better dissolution profile.
Suitable lubricants may include but are not limited to one or more from fatty acids, fatty acid salts, and fatty acid esters such as magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, colloidal silicon dioxide and mixtures thereof. The present invention comprises about 1 -15% w/w of lubricants of the total composition, preferably in the range of 1 -8% w/w of lubricants of the total composition.
The inventors of the present invention surprisingly found that being water-soluble lubricant, Sodium stearyl fumarate provided better dissolution profile than water insoluble lubricants like Magnesium stearate. In addition, the inventors of the present invention observed that colloidal silicon dioxide improved wet granulation process. Hence, the combination of these inactive ingredients provided a synergistic effect.
Suitable permeability enhancers may include but are not limited to one or more from the group comprising alcohols, Polyols, short-chain glycerides, amines, amides, cyclodextrins, fatty acids, pyrrolidines, azones, sulfoxides, surfactants, terpenes and the like.
Suitable chelating or complexing agents may include but are not limited to one or more from the group comprising cyclodextrin, ethylenediamine tetra acetic acid or
derivatives/salts thereof, e.g., disodium edetate, dihydroxyethyl glycine, glucamine, citric acid, tartaric acid, gluconic acid, phosphoric acid and the like.
Suitable coloring and flavoring agents may include but are not limited to one or more from sucralose, maltose, orange flavor, vanilla flavor and the like. Being zero- calorie artificial flavoring agent, Sucralose and orange flavour were used in the formulation. Hence, the patients with diabetes can also take this medicine and thus, the present invention provided better patient compliance. The present invention comprises about less than 3%w/w of flavoring agents of the total composition, preferably less than 1%w/w of flavoring agents of the total composition.
The inventors of the present invention also optimized the hardness of the tablet and disintegration time of the tablet by the selection of suitable punch tolling.
The prime aspect of the present invention is that the pharmaceutical composition establishes a fast release pattern owing to the kind of excipients used in the formulation and thereby producing an immediate release that will in turn increase in bioavailability at initial release.
In another aspect of the present invention, a synergistic pharmaceutical composition as per the present invention comprises several advantages including dose reduction, reduction in dose dependent side-effects and bypassing first pass metabolism of Edaravone on the particular target in human body.
One aspect of the present invention may include a pharmaceutical composition comprising about 1%w/w to 40%w/w of Edaravone with pharmaceutically acceptable excipients.
In yet another aspect of the present invention, wherein the pharmaceutical composition manufactured is sublingual tablet, which results in to enhanced dissolution profile.
Another aspect according to the present invention, wherein the formulated product manufactured is homogenous dispersions, which results in to enhanced dissolution profile and stability profile.
In yet another aspect of the present invention, wherein the pharmaceutical composition manufactured by number of stages in manufacturing process including mixing, wet-granulation and compression.
Additional aspect according to the present invention is that the formulated product is a stabilized sublingual tablet.
In one aspect process for preparation of an oral pharmaceutical composition as per the present invention comprising following steps:
1 . Co-milling of Mannitol, crospovidone and colloidal silicon dioxide through #40 sieve;
Binder solution preparation:
1. Mixing of ethanol and purified water, Isopropyl alcohol, ethanol and Dichloromethane were followed by addition of BFIT, Pulronic F68 (Poloxamer 188) and orange flavour;
2. Dissolving Edaravone in to the solution obtained in step-2 to prepare the binder solution;
Granulation:
3. Geometrically mixing of dry mix blend obtained in step-1 in slow manner to the binder solution obtained in step-3;
4. Drying and sifting of wet-granules obtained in stape-4;
Lubrication:
5. Adding and mixing of Crospovidone, sucralose, Sepitrap 80 to the dried and sized granules obtained in step-5;
6. Lubricating the blend obtained in step-6 with magnesium stearate or calcium stearate or sodium stearyl fumarate.
Compression:
7. Compressing the lubricated blend obtained in step-7 to form tablets.
The pharmaceutical formulations as described herein may be prepared by processes known to the person having ordinary skill in the art of pharmaceutical technology such as direct compression, wet granulation, dry granulation or hot melt granulation.
The invention will be further described with respect to the following examples; however, the scope of the invention is not limited thereby. All percentages stated in this specification are by weight, unless otherwise specified. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES:
Following section now will describe various formulation example as well as test examples by which the formulation example were evaluated. Further, results of the present invention were compared with the marketed formulation as well as nearest prior-arts.
EXAMPLE-1 & 2:
Process for preparation: Step-1 : Preparation of binding solution:
Edaravone, Hypromellose, L-cysteine, Sodium Bisulfite are mixed to prepare binding solution using purified water with ethanol (Example-1) OR isopropyl alcohol (Example-2). Step-2: Preparation of granules:
Binding solution prepared as per step-1 is admixed with premixed excipients lactose and crospovidone to prepare granules in a granulator. The granules are dried and sized. Step-3: Lubrication:
The dried and sized granules prepared as per step-2 are lubricated with magnesium stearate and Crospovidone.
Step-4a: Compression:
The lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
OR
Step-4b: Capsule filling: The lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
Step-5: Coating (Optional):
The tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
EXAMPLE-3 & 4:
Step-1 : Preparation of binding solution:
Edaravone, Hypromellose, L-cysteine, Sodium Bisulfite are mixed to prepare binding solution using purified water with ethanol (Example-3) OR isopropyl alcohol (Example-4).
Step-2: Preparation of granules:
Binding solution prepared as per step-1 is admixed with premixed excipients lactose and crospovidone to prepare granules in a granulator. The granules are dried and sized.
Step-3: Lubrication:
The dried and sized granules prepared as per step-2 are lubricated with magnesium stearate and Crospovidone.
Step-4a: Compression:
The lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
OR
Step-4b: Capsule filling:
The lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
Step-5: Coating (Optional):
The tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
EXAMPLE- 5:
Process for preparation:
Step-1 : Preparation of binding solution:
Edaravone, Pluronic F68 (Poloxamer 188), Butylated Hydroxy Toluene with orange flavour are mixed to prepare binding solution using ethanol with Dichloromethane (Example-5).
Step-2: Preparation of granules:
Binding solution prepared as per step-1 is admixed with premixed excipients mannitol, crospovidone and colloidal silicone dioxide to prepare granules in a granulator. The granules are dried and sized.
Step-3: Lubrication:
The dried and sized granules prepared as per step-2 are lubricated with magnesium stearate or calcium stearate, Sucralose, Sepitrap 80 (Polysorbate 80 and Magnesium Aluminometasilicate) and Crospovidone.
Step-4a: Compression:
The lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
OR
Step-4b: Capsule filling:
The lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
Step-5: Coating (Optional):
The tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
EXAMPLE- 6:
Process for preparation: Step-1 : Preparation of binding solution:
Edaravone, Pluronic F68 (Poloxamer 188), Butylated Hydroxy Toluene (BHT) with orange flavour are mixed to prepare binding solution using ethanol with Dichloromethane (Example-6). Step-2: Preparation of granules:
Binding solution prepared as per step-1 is admixed with premixed excipients Prosolv Easytab SP - LM /Prosolv Easytab SP / F melt , Sodium lauryl Sulfate and Colloidal silicone dioxide to prepare granules in a granulator. The granules are dried and sized.
Step-3: Lubrication:
The dried and sized granules prepared as per step-2 are lubricated with Sodium Stearyl Fumarate. Step-4a: Compression:
The lubricated granules prepared as per step-3 is subjected to compression to form a tablet. OR
Step-4b: Capsule filling:
The lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
Step-5: Coating (Optional):
The tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents. EXAMPLE- 7:
Process for preparation:
Step-1 : Preparation of binding solution:
Edaravone, Hydroxypropyl methylcellulose (HPMC), Povidone, Polyvinyl alcohol, Butylated Hydroxy Toluene with Orange Flavour are mixed to prepare binding solution using ethanol with Dichloromethane (Example-7).
Step-2: Preparation of granules:
Binding solution prepared as per step-1 is admixed with premixed excipients Mannitol or Lactose or Dextrose or microcrystalline cellulose or Ludipress or Pharmaburst or Ultraburst or What is Ludiflash or PEARLITOL Flash, L- cysteine, Croscarmellose Sodium or Sodium Starch glycolate or Starch and Colloidal silicone dioxide to prepare granules in a granulator. The granules are dried and sized.
Step-3: Lubrication:
The dried and sized granules prepared as per step-2 are lubricated with magnesium stearate.
Step-4a: Compression:
The lubricated granules prepared as per step-3 is subjected to compression to form a tablet.
OR
Step-4b: Capsule filling:
The lubricated granules prepared as per step-3 are filled in appropriate size of capsule.
Step-5: Coating (Optional):
The tablet prepared as per step-4a is optionally coated with pharmaceutically acceptable coating agents.
The invention described herein comprises in various objects as mentioned above and their description in relation to characteristics, compositions and process adopted. While these aspects are emphasised in the invention, any variations of the invention described above are not to be regarded as departure from the spirit and scope of the invention as described.
The following examples are provided for illustrative purpose only and these examples are in no way limitative on the present invention.
Claims
1. A sublingual pharmaceutical composition of Edaravone comprising: active pharmaceutical ingredient as a Edaravone and pharmaceutically acceptable excipients wherein pharmaceutically excipients may comprise of diluents, disintegrants, binders, lubricants, stabilizers or anti-oxidants, suspending agents, permeability enhancers, preservatives, glidants, active carriers, anti-caking agents, wetting agents, preservatives, buffering agents, flavouring agents, excluding (+)-2-borneol.
2. A sublingual pharmaceutical composition of Edaravone comprising: a. 1.00%w/w to 40.0%w/w of Edaravone, b. 0.10%w/w to 5.00%w/w of one or more stabilizers or anti-oxidants, c. 1.00% w/w to 25.00%w/w of one or more disintegrants, d. 0.10%w/w to 20.00%w/w of one or more wetting agents or surfactants or solubilizers, e. about 1 %w/w to 15%w/w of one or more lubricants, f. about less than 3%w/w of one or more flavouring agents and organic solvents.
3. The sublingual pharmaceutical composition of Edaravone as claimed in claim-2, wherein composition comprising preferably a. 3.00%w/w to 34.00%w/w of Edaravone, b. 0.10%w/w to 3.00%w/w of one or more stabilizers or anti-oxidants, c. 3.00%w/w to 20.00%w/w of one or more disintegrants, d. 0.10%w/w to 15%w/w of one or more or solubilizers or wetting agents or surfactants, e. about 1 %w/w to 8%w/w of one or more lubricants, f. about less than 1 %w/w of one or more flavouring agents and organic solvents.
4. The sublingual pharmaceutical composition of Edaravone as claimed in claim- 3, where in composition comprises stabilizers or anti-oxidants are selected from butylated hydroxytoluene (BHT), L-cysteine, sodium bisulphite, sodium metabisulfite, magnesium bisulfite, Pluronic F68 (Poloxamer 188), Butylated hydroxy anisole (BHA), fumaric acid and the like.
5. The sublingual pharmaceutical composition of Edaravone as claimed in claim-3, wherein the composition further essentially comprises disintegrants are selected from crospovidone, croscarmellose sodium, sodium starch
glycolate, starch, microcrystalline cellulose, low substituted hydroxypropyl cellulose and the like.
6. The sublingual pharmaceutical composition of Edaravone as claimed in claim-3, where in the composition comprises solubilizers or wetting agents or surfactants are selected from sepitrap 80 (Polysorbate 80 and Magnesium aluminometasilicate), polysorbate 80, castor oil, polyoxyethylene lauryl ether, polyoxyethylene and the like.
7. The sublingual pharmaceutical composition of Edaravone as claimed in claim-3, wherein the composition further essentially comprises lubricant is selected from fatty acids, fatty acid salts, and fatty acid easters such as magnesium stearate, calcium stearate, sodium stearyl fumarate, colloidal silicon dioxide and mixture thereof.
8. The sublingual pharmaceutical composition of Edaravone as claimed in claim-3, where in the composition comprises flavouring agents are selected from sucralose, orange flavour, maltose, vanilla flavour, mannitol and like.
9. The sublingual pharmaceutical composition of Edaravone as claimed in claim- 3, where in the composition comprises suitable organic solvents for preparing binding solution may include one or more of water, organic solvents such as ethanol, isopropyl alcohol, dichloromethane, acetone and mixture of organic solvents thereof.
10. Process for the preparation of an oral sublingual pharmaceutical composition of Edaravone as claimed in above claims 1-9 comprising the following steps:
Co-milling of Mannitol, crospovidone and colloidal silicon dioxide through #40 sieve; a) Binder solution preparation:
1. Mixing of ethanol and purified water, Isopropyl alcohol, ethanol and Dichloromethane were followed by addition of BHT, Pulronic F68 (Poloxamer 188) and orange flavour;
2. Dissolving Edaravone in to the solution obtained in step-2 to prepare the binder solution; b) Granulation:
3. Geometrically mixing of dry mix blend obtained in step-1 in slow manner to the binder solution obtained in step-3;
4. Drying and sifting of wet-granules obtained in stape-4; c) Lubrication:
5. Adding and mixing of Crospovidone, sucralose, Sepitrap 80 to the dried and sized granules obtained in step-5;
6. Lubricating the blend obtained in step-6 with magnesium stearate or calcium stearate or sodium stearyl fumarate. d) Compression:
7. Compressing the lubricated blend obtained in step-7 to form tablets.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121019616 | 2021-04-29 | ||
IN202121019616 | 2021-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022229982A1 true WO2022229982A1 (en) | 2022-11-03 |
Family
ID=83847872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2022/050399 WO2022229982A1 (en) | 2021-04-29 | 2022-04-28 | Oral formulations of edaravone and method of manufacturing thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022229982A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019205700A1 (en) * | 2018-04-27 | 2019-10-31 | 首都医科大学附属北京天坛医院 | Edaravone pharmaceutical composition |
-
2022
- 2022-04-28 WO PCT/IN2022/050399 patent/WO2022229982A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019205700A1 (en) * | 2018-04-27 | 2019-10-31 | 首都医科大学附属北京天坛医院 | Edaravone pharmaceutical composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010213594B2 (en) | Delayed release, oral dosage compositions that contain amorphous CDDO-Me | |
KR101524164B1 (en) | Controlled release pharmaceutical composition | |
US10561654B2 (en) | Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | |
AU2007338359B2 (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
CN110114063B (en) | Lurasidone solid dispersion and preparation method thereof | |
AU2005271206B2 (en) | Pharmaceutical composition comprising drospirenone and ethynylestradiol | |
JP2013534242A (en) | Formulations containing nalbuphine and their use | |
JP2023507787A (en) | Compositions with improved solubility and bioavailability of olaparib | |
KR20160137521A (en) | Pharmaceutical compositions comprising levocetirizine | |
TW201713343A (en) | Pharmaceutical composition for oral administration | |
WO2022229982A1 (en) | Oral formulations of edaravone and method of manufacturing thereof | |
US20200078463A1 (en) | Composition having improved water solubility and bioavailability | |
EP2190415A2 (en) | Pharmaceutical compositions of fenofibrate | |
US10406127B2 (en) | Solid oral formulation of fenretinide | |
CN116600827A (en) | Olaparib solid dispersion compositions with improved stability and bioavailability | |
CN109864978B (en) | Sustained-release preparation of 5-methyltetrahydrofolic acid and preparation method thereof | |
WO2024033703A1 (en) | Amorphous solid dispersions comprising naporafenib | |
US20100285126A1 (en) | Pharmaceutical compositions of fenofibrate | |
WO2024028262A1 (en) | Novel formulation | |
WO2022155507A1 (en) | Transmucosal dosage forms of brexanolone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22795162 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22795162 Country of ref document: EP Kind code of ref document: A1 |